How is PrIMAVeRa funded?
PrIMAVeRA receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 101034420. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA (The European Federation of Pharmaceutical Industries and Associations).
It is coordinated by the European Vaccine Initiative (Germany), with support from Professor Marc Bonten of the University Medical Center Utrecht (Netherlands) as scientific coordinator and GlaxoSmithKline as industry lead. It involves 19 partners across the EU, the UK and Russia, including 16 academic institutions and small and medium enterprises (SME), as well as GlaxoSmithKline, Pfizer and Janssen as industry partners.